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Pulmonary Cryptococcosis: Imaging
Findings in 23 Non-AIDS Patients
Objective: We aimed to review the patterns of lung abnormalities of pulmonary
cryptococcosis on CT images, position emission tomography (PET) findings of
the disease, and the response of lung abnormalities to the therapies in non-AIDS
patients.
Materials and Methods: We evaluated the initial CT (n = 23) and 18F-fluo-
rodeoxyglucose (FDG) PET (n = 10), and follow-up (n = 23) imaging findings of
pulmonary cryptococcosis in 23 non-AIDS patients. Lung lesions were classified
into five patterns at CT: single nodular, multiple clustered nodular, multiple scat-
tered nodular, mass-like, and bronchopneumonic patterns. The CT pattern analy-
ses, PET findings, and therapeutic responses were recorded.
Results: A clustered nodular pattern was the most prevalent and was observed
in 10 (43%) patients. This pattern was followed by solitary pulmonary nodular (n =
4, 17%), scattered nodular (n = 3, 13%), bronchopneumonic (n = 2, 9%), and sin-
gle mass (n = 1, 4%) patterns. On PET scans, six (60%) of 10 patients showed
higher FDG uptake and four (40%) demonstrated lower FDG uptake than the
mediastinal blood pool. With specific treatment of the disease, a complete clear-
ance of lung abnormalities was noted in 15 patients, whereas a partial response
was noted in seven patients. In one patient where treatment was not performed,
the disease showed progression. 
Conclusion: Pulmonary cryptococcosis most commonly appears as clustered
nodules and is a slowly progressive and slowly resolving pulmonary infection. In
two-thirds of patients, lung lesions show high FDG uptake, thus simulating a pos-
sible malignant condition.
ryptococcus neoformans is a ubiquitous encapsulated yeast-like fungus
that is found worldwide; particularly in soils that are contaminated with
pigeon excreta and decayed wood (1-3). Inhalation of cryptococcal
particles into the lungs is a route of pulmonary infection, and subsequent hematoge-
nous dissemination may cause central nervous system infection (1). Cryptococcal
infections are mostly common in immunocompromized patients such as those with
AIDS, who underwent organ transplantation, or who have a hematologic malignancy.
These infections are relatively rare in immunocompetent patients (2).
Pulmonary cryptococcosis in AIDS patients tends to manifest itself as a disseminated
thoracic disease with an interstitial lung pattern and lymph node enlargement as seen
on imaging studies (4-8); whereas the infection in immunocompetent hosts shows
single or multiple nodular lesions or mass-like consolidation (8-11). The infection in
non-AIDS patients is rather indolent in nature and is usually not treated systemically
when the disease appears as a localized nodular or a consolidative lesion (12).
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CTherefore, lung lesions of single or multiple nodules or a
mass, for this condition, may persist and may simulate
malignant disease, a chronic inflammatory or an infectious
disease, or a metastatic lesion, particularly when patients
have an underlying extra-thoracic malignancy. 
Different treatment options have been advocated for this
infection in non-AIDS patients including surgical resection,
antifungal treatment, or observation without specific
treatment (12, 13). However, the natural course of the
disease on imaging studies, particularly how quickly the
lung lesions evolve before adequate treatment of the
disease and how the lung lesions show response to surgical
or antifungal therapy, has not been well documented. Only
a few reports document the PET findings of pulmonary
cryptococcosis (14-17). Thus, the purpose of our study was
to review patterns of lung abnormalities of pulmonary
cryptococcosis on CT images, assess the PET findings of
the disease, and evaluate the response of lung abnormali-
ties to the different therapies.
MATERIALS AND METHODS
Our Institutional Review Board approved our retrospec-
tive study with a waiver of the informed consent from each
patient.
Patients 
This was a retrospective study for patients with
pulmonary cryptococcal infection who were seen in a
single tertiary-referral hospital over the course of a 14-year
period (January 1995 to December 2008) and who
underwent thoracic CT examinations. By using the
electronic database of medical records, we could identify
23 patients, who had histopathologically-proven
pulmonary cryptococcosis. Over the same span of time, we
could not find any patient who had AIDS and cryptococcal
infection. The patient population consisted of 13 men and
10 women, with an age range from 32 years to 77 years
(median, 57 years; mean age ± standard deviation [SD],
56 ± 12.4 years). None of the patients showed central
nervous system involvement for the disease.
If a patient had at least one of the following conditions:
underlying malignancy, use of immunosuppressive drugs,
uncontrolled diabetes mellitus, or liver cirrhosis, the
patient was considered to be immunocompromised. Even
though a patient had a history of malignancy, the patient
was considered to be immunocompetent when he or she
was in a disease-free state for more than five years.
Thirteen patients had various underlying diseases including
breast cancer in three patients, hepatocellular carcinoma in
two patients, as well as colon cancer, cholangiocellular
carcinoma, renal cell carcinoma, pancreatic cancer, diffuse
large B-cell lymphoma, advanced gastric cancer,
esophageal cancer, and herpes simplex encephalitis in one
patient each. Of the 12 patients with an underlying
malignancy, three patients were in a disease-free state for
more than five years. However, one of the three patients
in the disease-free state had liver cirrhosis. Thus, this
patient was classified as immunocompromised. As a result,
11 (10 patients with an underlying malignancy and one
with herpex simplex encephalitis) patients were considered
to be immunocompromised and 12 patients were consid-
ered to be immunocompetent (Table 1).
The diagnosis of the pulmonary fungal infection was
made with the aid of histopathological specimens. The
specimens were obtained via a percutaneous gun (core)
biopsy for lung lesions in eight patients, a wedge resection
using video-assisted thoracoscopic surgery (VATS) in 13
patients, and a right middle lobectomy performed by way
of VATS or wedge resection after an open thoracotomy,
respectively for one patient for each method. The
histopathological diagnoses were rendered by identifying
encapsulated yeast forms within inflammatory lung tissue
with the use of Hematoxylin and eosin, mucicarmine,
periodic acid-Schiff, or Gomori-methenamin-silver
staining. A serum cryptococcal antigen test demonstrated
positivity in only three (21%) of 14 patients in which the
test was performed. 
Patient Demographics
The symptoms or signs of patients, if any, were recorded.
In addition, clinicoradiological diagnoses before the defini-
tive diagnosis of cryptococcosis were recorded. Eleven
patients had previously undergone CT scans (scan interval;
range = 1 - 75 days, median time = 18 days, mean time =
21.7 days) that had been obtained at outside institutions.
PET (n = 1) or PET/CT (n = 9) scans were available for 10
patients.
Image Acquisition and Interpretation
Helical Enhanced CT Imaging
All chest CT examinations for patients at the time of
presentation were performed using a single-detector (two
patients; HiSpeed Advantage scanner, GE Healthcare,
Milwaukee, WI), 4-detector (eight patients; LightSpeed
QX/I, GE Healthcare), 8-detector (five patients;
LightSpeed Ultra, GE Healthcare), 16-detector (four
patients; LightSpeed Ultra or Ultra16, GE Healthcare), or
64-detector (four patients; LightSpeed VCT XT, GE
Healthcare) row scanners. Helical CT scans (125-200 mA,
120 kVp; 5-mm section thickness and a pitch of 1 for
single-detector helical CT and beam width of 10-20 mm,
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obtained from the lung apices to the level of the middle
portion of both kidneys after an intravenous contrast
medium injection of 80 mL Iomeron 300 (Iomeprol;
Bracco, Milan, Italy). The image data were reconstructed
with a high-spatial algorithm for lung window images, a
standard algorithm for mediastinal window images, a 5-
mm section thickness for single-detector helical CT scans,
and with a 2.5-mm section thickness for multidetector CT
scans. All image data were directly interfaced with a
picture archiving and communication systems (PACS)
(PathSpeed, or Centricity 2.0; GE Healthcare, Mt.
ProSpect, IL), which displayed all image data on two
monitors (1,536 × 2,048 matrix, 8-bit viewable gray
scale, and 60-ft-Lambert luminescence). Both mediastinal
(width, 400 HU; level, 20 HU) and lung (width, 1,500
HU; level, -700 HU) window images were viewed on
these monitors.
Scans were assessed for the presence of lung abnormali-
ties (nodules, masses, consolidation, and ground-glass
opacity) and distribution (laterality and lobar location,
lingular division was classified as a separate lobe) at the
time of presentation. Two chest radiologists performed the
evaluations and decisions on the findings that were
reached by consensus. Nodules were defined as round or
oval opacities with at least moderately well circumscribed
margins that had a maximum diameter of 3 cm or less. If a
rim of ground-glass opacity surrounded a nodule, the halo
sign was considered present. When opacities were greater
than 3 cm in diameter, the lesions were defined as masses.
The criteria for consolidation were met when parenchymal
non-nodular opacity obscured the underlying pulmonary
architecture and often accompanied air bronchograms.
Ground-glass opacity was defined as hazy opacities
through which the normal pulmonary architecture could be
visualized. The presence of cavitation within nodules or
masses was noted. The presence of pleural effusion and
lymphadenopathy (when the short-axis diameter was
greater than 10 mm) were also recorded.
After the assessment of lung parenchymal abnormalities,
the lung lesions were further classified into five patterns:
single nodular, multiple clustered nodular, multiple
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Table 1. Demographic and Clinical Information of Patients
PatientsAge/Sex Pres enting Symptom
Immune Status/ Radiologic Diagnosis  Treatment Regimen 
Underlying Disease before Biopsy (months)
01 32/M No Competent/No Tuberculosis WR 
02 58/M No Competent/No Tuberculosis WR 
03 35/F Cough, fever Competent/No Tuberculosis Fluconazole, 12
04 64/F No Competent/No Lung cancer WR
05 53/M Chest pain Competent/No Tuberculosis WR
06 40/M Chest pain Competent/No Lung cancer Lobectomy + Fluconazole, 2
07 38/M Cough and chest pain Competent/No Tuberculosis Fluconazole, 4
08 52/F Cough and sputum Competent/No Lung cancer Fluconazole, 12
09 51/M Chest pain Competent/No Tuberculosis  Fluconazole, 4
10 41/F Cough Competent/No Tuberculosis  Fluconazole, 6
11 53/M No Competent/HCC NED Tuberculosis No
12 68/F No Competent/Breast cancer NED Metastasis WR + Fluconazole, 6
13 71/F Cough Compromised/AGC Metastasis WR + Fluconazole, 6
14 57/F No Compromised/Breast cancer  Metastasis WR + Fluconazole, 5
15 70/F No Compromised/RCC  Metastasis WR
16 63/M No Compromised/CCC Tuberculosis WR
17 49/M No Compromised/Pancreatic cancer, DM  Paragonimiasis Fluconazole, 4
18 77/F Cough and sputum Compromised/DLBL Lymphoma involvement WR + Fluconazole, 4
19 58/M No Compromised/Esophageal cancer Metastasis WR
20 65/M No Compromised/HCC NED, LC OP WR+ Fluconazole , 2
21 50/M No Compromised/Colon cancer Metastasis WR
22 72/F No Compromised/Breast cancer OP WR + Fluconazole, 4
23 61/M Fever Compromised/Herpes simplex encephalitis Cryptococcosis Amphotericin B, 19 days 
and Fluconazole, 4
Note.─ AGC = advanced gastric cancer, CCC = cholangiocellular carcinoma, DLBL = diffuse large B-cell lymphoma, DM = diabetes mellitus, HCC = 
hepatocellular carcinoma, LC = liver cirrhosis, NED = no evidence of disease, OP = organizing pneumonia, RCC = renal cell carcinoma, WR = wedge
resectionscattered nodular, mass-like, and bronchopneumonic
patterns. Single nodular and mass-like patterns were
defined when the lung lesion consisted of a single nodule
and a single mass, respectively. The multiple clustered
nodular pattern was defined when the lesions consisted of
multiple variable-sized nodules confined to one lobe,
whereas the multiple scattered nodular pattern was defined
when lesions consisted of multiple variable-sized nodules
scattered throughout multiple lobes in a single lung or in
both lungs. The bronchopneumonic pattern was defined as
when lung lesions were comprised of areas of lobular,
subsegmental, or segmental consolidation, ill-defined
centrilobular small nodules (measuring 4 to 10 mm in
diameter and representing peribronchiolar consolidation)
or tree-in-bud (small centrilobular nodules and branching
nodules within the secondary pulmonary lobule) opacities
(18). When lung lesions could not be classified into one of
the five patterns, they were classified as unclassifiable.
In 11 patients, where previous CT scans were available,
the scans were also analyzed with the use of the above-
mentioned methods and the findings were compared with
those seen on CT scans at the time of presentation.
PET or PET/CT 
Details on imaging methods have been described in
previous reports (19, 20). Briefly, the peripheral blood
glucose levels were ≤ 150 mg/dL in all patients. Patients
received an intravenous injection of 370 MBq (10 mCi)
18F-fluorodeoxyglucose (FDG) and were then allowed to
rest for over 45 minutes prior to scanning. Image acquisi-
tion was achieved by way of a PET (Advance, GE
Healthcare, Milwaukee, WI) or PET/CT device (Discovery
LS, GE Healthcare) consisting of an Advance NXi PET
scanner and an 8-slice LightSpeed Plus CT scanner.
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Fig. 1. Pulmonary cryptococcosis with clustered nodular pattern in
53-year-old man who had hepatocellular carcinoma (patient 11 in
Tables 1, 2).
A. Lung window of transverse CT scan obtained at level of distal
trachea demonstrates clustered nodules in posterior segment of
right upper lobe.
B. PET/CT scan obtained at similar level to A demonstrates high
FDG uptake (arrow) within main nodule (maximum standardized
uptake value, 9.3), hence simulating malignant nodule.
C. Follow-up CT scan obtained at similar level to and three months
after A demonstrates slightly increased extent of clustered nodules
in right upper lobe.
AB
CPET or PET/CT examinations were performed as part of
a metastatic workup in six patients because these patients
had extra-thoracic malignant disease. In the remaining four
patients, studies were performed for nodule characteriza-
tion.
Integrated PET/CT images were evaluated by a nuclear
medicine physician who was unaware of the clinical or
histopathological findings. The maximum FDG standard-
ized uptake value (mSUV) of lung lesions was measured
for the lung abnormalities.
Treatment and Follow-Up Imaging Studies
The treatments administered were as follows: no specific
treatment after the diagnosis of pulmonary cryptococcosis
in one patient; surgical resection only for both diagnosis
and treatment as well as the use of VATS or open thoraco-
tomy in eight patients; antifungal therapy (Fluconazole;
Plunazole, Daewoong Pharm, Seoul, Korea) following a
diagnostic lung lesion resection in seven patients. The
remaining seven patients underwent antifungal therapy
after a diagnostic core biopsy. The mean treatment
duration of antifungal therapy in 14 patients was five
months (range, 2-12 months).
Follow-up imaging studies (with CT in 16 patients and
with chest radiographs in seven patients) were obtained for
all patients. The follow-up period ranged from two to 26
months (median, 7 months; mean, 9 months). Responses
on imaging studies were classified into partial, complete, or
no response.
RESULTS
Of the 23 patients, 13 (57%) had no symptoms or signs.
In 10 (43%) patients, symptoms including cough (n = 6),
chest pain (n = 4), sputum (n = 2), and fever (n = 2) were
observed. Before the definitive diagnoses of cryptococcosis
had been determined, clinicoradiological diagnoses for the
disease included pulmonary tuberculosis (n = 9),
metastases from an extra-thoracic malignancy (n = 6), lung
cancer (n = 3), organizing pneumonia (n = 2), pulmonary
paragonimiasis (n = 1), lymphomatous involvement of the
lung (n = 1), and pulmonary cryptococcosis (n = 1) (Table
1).
Lesion Evolvement Depicted on CT Imaging
Of the 11 patients who had undergone previous CT
scans (nine of the 11 patients received empirical antibiotic
treatment based on the assumption that the patients had
community acquired pneumonia), seven (67%) showed a
progression of the same pattern of disease, whereas four
(33%) showed no change in the extent of the disease.
None of the patients showed improvement in the course of
the disease (Table 2). Of the nine patients, whose largest
lesion’s maximum diameter was measurable in both
previous and current CT scans, seven patients showed no
change in the maximum diameter of the lesion within a 34
day follow-up period, however two patients demonstrated
an interval increase (2.5 and 2.6 times) in lesion diameters
over 50 and 75 day follow-up period, respectively.
CT Findings
A clustered nodular pattern (Fig. 1) of lung abnormalities
was the most frequent pattern and was observed in 10
(43%) patients. A solitary pulmonary nodular pattern 
(n = 4, 17%) (Fig. 2) and scattered nodular pattern (n = 3,
13%) (Fig. 3) were the next most common patterns for
lung lesions. A bronchopneumonic pattern (Fig. 4) was
noted in two (9%) patients, and a single mass lesion 
(Fig. 5) was identified in one patient (4%). In three
patients, lung lesions were unclassifiable: one patient had a
mass and a nodule, another patient had an area of consoli-
dation and multiple scattered nodules in the left lung, and
the third patient had clustered masses and nodules in the
bilateral lower lung zones (Table 2). 
In immunocompetent patients (n = 12), a clustered
nodular pattern (n = 6, 50%), scattered nodular pattern 
(n = 2, 17%), solitary pulmonary nodular pattern (n = 1,
8%), solitary mass (n = 1, 8%), and unclassifiable lesions
(n = 2, 16%) were observed. In immunocompromised
patients (n = 11), a clustered nodular pattern (n = 4, 36%),
solitary pulmonary nodular pattern (n = 3, 27%),
bronchopneumonia pattern (n = 2, 18%), scattered
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Fig. 2. Pulmonary cryptococcosis of solitary pulmonary nodular
pattern in 58-year-old man who had esophageal cancer (patient
19 in Tables 1, 2). Lung window of transverse CT scan obtained
at level of suprahepatic inferior vena cava shows 7-mm-sized
solitary pulmonary nodule (arrow) in right lower lobe.nodular pattern (n = 1), and unclassifiable lesions (n = 1,
9%) were observed.
Of the six lobes observed (lingular division was consid-
ered as a separate lobe), the left lower lobe was most
frequently involved (nine cases). The right lower lobe was
involved in seven cases, the left upper lobe and the lingular
division were involved in six cases each, the right middle
lobe was involved in five cases, and the right upper lobe
was involved in four cases.
Cavitation within lung parenchymal lesions was noted in
four (17%) patients. A nodule with a halo sign was also
observed in two (9%) patients. Mediastinal lymph node
enlargement was not noted in any patient. Pleural effusion
was noted in one (4%) patient, but pericardial effusion was
not observed in any patient.
PET Findings
Of the 10 patients that underwent PET, six showed
higher FDG uptake compared to the mediastinal blood
pool, thus simulating malignant FDG uptake, whereas four
patients demonstrated a benign type of FDG uptake. The
mSUVs for FDG uptake of lung parenchymal lesions
Song et al.
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Fig. 4. Cryptococcosis of bronchopneumonic pattern in 72-year-old woman who has underlying breast cancer (patient 22 in Tables 1, 2).
A. Lung window of transverse CT scan obtained at level of right inferior pulmonary vein shows subpleural consolidation and nodule
(arrow) with surrounding halo in right lower lobe.
B. Follow-up CT scan obtained five months after A and with four months of anti-fungal therapy demonstrates remaining lesions of
consolidation (arrowhead) and nodule (arrow) in right lower lobe.
AB
Fig. 3. Pulmonary cryptococcosis with scattered nodular pattern in 38-year-old man who had no underlying disease (patient 7 in Tables
1, 2).
A. Lung window of transverse CT scan obtained at level of great vessels shows nodule (arrow) with surrounding ground-glass opacity
(halo sign) and centrilobular small nodules (arrowheads) in right upper lobe.
B. CT scan obtained at level of basal trunk demonstrates nodules with halo sign in superior segment of right lower lobe.
ABranged from 1.8 to 9.3 (median, 5.3; mean, 5.4) (Table 2).
Follow-Up Study
No patient died from the pulmonary cryptococcosis.
Clinical or radiological improvement was identified in 22
(96%) patients. In one patient (4%) with underlying
hepatocellular carcinoma and no specific treatment was
given, the parenchymal lesions of clustered nodules
showed disease progression over a five-month follow-up
period (Fig. 1). 
Of the 22 patients treated, complete clearance of lung
abnormalities was noted in 15 (65%) patients including
four patients who had solitary pulmonary nodular lesions.
In one patient, lesions disappeared completely with
antifungal therapy only (patient 23 in Tables 1, 2).
Fourteen (93%) of the 15 patients with complete clearance
underwent surgical resection for the diagnostic workup. In
nine (64%) of the 14 patients, lesions were relatively
localized (clustered nodules, solitary pulmonary nodule, or
a mass and a nodule). Therefore, a diagnostic surgical
resection removed all lesions. After the surgical resection,
new nodular lesions developed in one patient (patient 14
in Tables 1, 2) on follow-up CT scans obtained two months
later. This patient was treated with antifungal agents for
five months and the new lesions disappeared after the
treatment. In the remaining eight patients, there was no
newly developed lesion on follow-up scans. In another five
(36%) patients, diagnostic surgical resection could not
remove all lesions. Thus, additional antifungal therapy was
administered. Therefore, a total of six patients, where
complete lesion clearance was achieved, received antifun-
gal therapy after the surgical resection. In these six
patients, the mean treatment duration was 4.2 months
(range, 2-6 months).
In seven (31%) patients, although improvement of lung
lesions with a decreased extent of abnormalities was
observed, the remaining lung lesions persisted (partial
response) during the median follow-up period of 11
months (range, 5-26 months; mean, 13 months) (Fig. 4)
(Table 2).
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Table 2. Imaging Findings of Cryptococcosis in 23 Patients
Previous CT  Follow-Up CT Findings at Presentation PET  Follow-Up  Follow-
PatientsPatterns   Interval  Main Patterns  Predominant Zone/  Findings  CT or CXR  Up 
(mm) (days) (mm)*
Laterality
Location (mSUV) Findings(months )
01 CNs (6) 50  CNs (15) U LLL 2.9 CR 02
02 CNs (17) 12  CNs (17) U RLL 2.8 CR 04
03 -- CNs (28) U LLL - PR 26
04 -- CNs (16) U Lingular - CR 11
05 CNs (20) 08  CNs (20) U RLL 2.0 CR on CXR 12
06 SPN (17) 07  SPN (17) U RML 7.9 CR 04
07 SNs (25) 13  SNs (28) B Both lungs - PR on CXR 5
08 -- Solitary mass (44) U RML - PR 11
09 SNs (27) + consolidation 03 SNs (28) + consolidation U Left lung - PR on CXR 21
10 Clustered masses  18 Clustered masses (60)  U LLL - PR 12
and nodulesand nodules
11 -- CNs (20) U RUL 9.3 Slight progression 05
12 SNs (5) 75 SNs (13) B Both lungs 8.8 CR on CXR 07
13 -- CNs (15) U LUL - CR on CXR 05
14 -- SPN (10) U RLL 1.8 CR 07
15 -- A mass (38) + a nodule (16) U LUL - CR 06
16 CNs (15) 01 CNs (15) U LLL 4.8 CR 15
17 -- CNs (14) U RML - PR 10
18 -- CNs (12) U Lingular 7.2 CR on CXR 11
19 -- SPN (7) U RLL - CR 03
20 SNs (19) 34 SNs (21) U LLZ 5.7 CR 10
21 -- SPN (8) U RUL - CR on CXR 06
22 Bronchopneumonia 18 Bronchopneumonia U RLL - PR 08
23 -- Bronchopneumonia U Left lung - CR 05
Note.─ * maximum diameter (of largest lesion), B = bilateral, CNs = clustered nodules, CR = complete remission, CXR = chest radiograph, LLL = left 
lower lobe, LLZ = lower lung zone, LUL = left upper lobe, mSUV = maximum standardized uptake value, - = not available, PR = partial remission, RLL =
right lower lobe, RML = right middle lobe, RUL = right upper lobe, SNs = scattered nodules, SPN = solitary pulmonary nodule, U = unilateralOf seven patients who were treated with antifungal
agents only, one patient (patient 23 in Tables 1, 2, treated
with amphotericin and fluconazole) showed complete
clearance. In the remaining six patients, who were treated
with fluconazole, a partial response was noted. The mean
follow-up period was 14 months (range, 5-26 months). In
these six patients with remaining disease, symptoms such
as a cough, sputum, fever, and chest pain disappeared
within three or six months of the treatment outset.
DISCUSSION
In our study, the most frequent pattern of lung
abnormalities depicted on CT scans was clustered nodules,
which was observed in 10 (43%) patients. This pattern was
followed by solitary pulmonary nodular (n = 4, 17%) and
scattered nodular (n = 3, 13%) patterns. Thus, nodular
lesions localized to a lobe or scattered to lung(s) accounted
for 73% of lung parenchymal abnormalities. Our results
concur with findings of previous reports in which clustered
nodules or a solitary pulmonary nodule was the most
common pattern of lung abnormalities for pulmonary
cryptococcosis (9-11, 21).
Of the 11 patients that underwent previous CT scans
before presentation, all patients showed slow progression
or no change with respect to the extent of the lung lesions.
In particular, two patients, in which the lesions increased in
size by more than two times the original diameter at
approximately 50 days after the initial assessment. None of
the patients showed spontaneous resolution of parenchy-
mal lung lesions. Therefore, a specific diagnosis of crypto-
coccosis is mandatory for the management of this infection.
On the other hand, the chronicity of lung lesions was noted
after the diagnosis of the disease was confirmed. Lung
lesions were indolent and the lung lesions did not show a
rapid response to antifungal therapy.
In our study, 11 (48%) of 23 patients were immunocom-
promised and 12 were immunocompetent. However, the
disease patterns between the two groups were not differ-
ent. Furthermore, none of the immunocompromised
patients showed a disseminated disease pattern such as
diffuse interstitial lung disease accompanied by extensive
hilar and mediastinal lymphadenopathy.
It is well known that active tuberculosis or tuberculoma,
acute and chronic pneumonia, lung abscess, fungal
infection, and parasitic infestation are frequent causes of
increased FDG uptake (22). For these conditions, the
presence and activity of leukocytes account for the
increased FDG uptake. Activated macrophages and
neutrophils in inflammatory tissue utilize glucose as an
energy source for chemotaxis and phagocytosis, whereas
fibroblasts utilize glucose for proliferation. In our study, six
(60%) of 10 patients that underwent PET or PET/CT scans
showed high FDG uptake. Moreover, five (83%) of these
six patients had an underlying malignancy. Pulmonary
metastases could not be excluded in these five patients
because of the presence of multiple pulmonary nodules
with a high rate of FDG uptake were noted on the PET
scans, even though the nodules showed clustering on CT
scans, persisted for a quite amount of time. Thus, even in
patients with an underlying malignancy and lung nodules
that demonstrate high FDG uptake, when nodules are
clustered in a lobe, a histopathological diagnosis should be
performed for tissue confirmation.
The complete clearance of lung abnormalities was
achieved in 15 patients. Of these 15 patients, surgical
resection with or without subsequent antifungal therapy
was needed for complete clearance in 14 patients. In the
remaining patient, complete clearance was achieved with
antifungal therapy only. In the seven patients that were
administered antifungal therapy only, a partial response
was noted in six patients. In these six patients, although
clinical improvement was achieved, the lung lesions
persisted after the treatment, as seen on serial imaging
studies. In one patient that was not given a treatment, the
disease showed progression. Thus, lung lesions were
indolent and they did not show a rapid response to antifun-
gal therapy. 
Actinomycosis, semi-invasive aspergillosis, and
pulmonary tuberculosis are well-known representative
causes of chronic pneumonias that usually show an
indolent disease course, before and after treatment. These
three diseases usually present as single or multiple
nodule(s) or mass or as a single area of dense consolidation
Song et al.
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Fig. 5. Pulmonary cryptococcosis of solitary mass pattern in 52-
year-old woman with no underlying disease (patient 8 in Tables 1,
2). Lung window of CT scan obtained at level of right middle lobar
bronchus shows mass in right middle lobe.(23-25). Therefore, for chronic indolent lung lesions of
various patterns including pulmonary cryptococcosis,
tuberculosis, actinomycosis, and semi-invasive aspergillosis
should be considered for the differential diagnosis of
chronic pneumonia.
Our study has several limitations; first, our study was
retrospective by design. A prospective study on the
imaging diagnosis or treatment method should be
performed. Second, there is a possibility that selection bias
may have occurred. This is apparent as 12 of 23 patients
had an underlying malignancy. Moreover, all 23 patients
had biopsy-proven disease. More mild disease may have
evaded our patient selection. Third, because of the limited
number of patients with the disease, diverse CT findings of
the disease and variable follow-up periods, we were not
able to provide meaningful CT data or findings that help
predict patient prognosis (complete disappearance versus
remaining disease).
In conclusion, pulmonary cryptococcosis is an indolent
lung disease in non-AIDS patients that is slowly progres-
sive in nature, even without adequate treatment.
Moreover, it does not show a rapid resolution of the lung
abnormalities even with antifungal therapy. The disease
may appear with various patterns of lung lesions; however,
a multiple clustered-nodular pattern, localized to a lung
lobe, is the most common abnormality. In half of the cases,
the disease appeared in patients with underlying disease, in
which most of the patients have an extra-thoracic
malignant condition. Therefore, when lung lesions show
clustered or scattered nodules of an indolent nature,
pulmonary cryptococcosis should be considered in the
differential diagnosis, even for a patient with an extra-
thoracic malignancy. The lesions may show high FDG
uptake and may thus simulate a malignant lung condition
at PET. Although clinical improvement can be achieved in
all patients, radiological improvement is slow, even after
antifungal therapy. Lastly, lung lesions may persist for a
long time, showing a divergence from the clinical response.
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